Aptevo Therapeutics
$4.34
45
+$0.07+1.64% Today
Statistics
Day High
4.38
Day Low
4.05
52W High
1,299.6
52W Low
3.84
Volume
19,339
Avg. Volume
174,455
Mkt Cap
73.13M
P/E Ratio
0
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7MayExpected
Expected EPS
-5.6
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-48.26MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow APVO. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Xencor
XNCR
Mkt Cap994.24M
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Novartis
NVS
Mkt Cap237.61B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Merck
MRK
Mkt Cap214.76B
Pfizer
PFE
Mkt Cap140.15B
About
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Show more...
CEO
Mr. Marvin L. White
Employees
37
Country
US
ISIN
US03835L7029
Listings
0 Comments
Share your thoughts
FAQ
What is Aptevo Therapeutics stock price today?▼
The current price of APVO is $4.34 USD — it has increased by +1.64% in the past 24 hours. Watch Aptevo Therapeutics stock price performance more closely on the chart.
What is Aptevo Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aptevo Therapeutics stocks are traded under the ticker APVO.
Is Aptevo Therapeutics stock price growing?▼
APVO stock has fallen by -5.54% compared to the previous week, the month change is a -42.9% fall, over the last year Aptevo Therapeutics has showed a -98.84% decrease.
What is Aptevo Therapeutics market cap?▼
Today Aptevo Therapeutics has the market capitalization of 73.13M
When is the next Aptevo Therapeutics earnings date?▼
Aptevo Therapeutics is going to release the next earnings report on May 07, 2026.
What were Aptevo Therapeutics earnings last quarter?▼
APVO earnings for the last quarter are -40.14 USD per share, whereas the estimation was -37.62 USD resulting in a -6.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aptevo Therapeutics revenue for the last year?▼
Aptevo Therapeutics revenue for the last year amounts to 0 USD.
What is Aptevo Therapeutics net income for the last year?▼
APVO net income for the last year is -48.26M USD.
How many employees does Aptevo Therapeutics have?▼
As of April 01, 2026, the company has 37 employees.
In which sector is Aptevo Therapeutics located?▼
Aptevo Therapeutics operates in the Health Care sector.
When did Aptevo Therapeutics complete a stock split?▼
The last stock split for Aptevo Therapeutics was on December 30, 2025 with a ratio of 1:18.
Where is Aptevo Therapeutics headquartered?▼
Aptevo Therapeutics is headquartered in Seattle, US.